weight-loss drugs

systematic review meta-analysis network meta-analysis

Select cardiovascular preventiondiabetes type 2 All type of patientDiabetic patientsoverweight or obese patients       endocannabinoid receptor rimonabant rimonabant vs placebo or control      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	weight loss equal to or greater than 10 percent (6)weight loss equal to or greater than 5 percent (2)Waist circumference change from baseline (cm) (1)Fasting glucose change (mmol/liter) (1)weight change from baseline (kg) (1) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	weight loss equal to or greater than 10 percent	weight loss equal to or greater than 5 percent
cardiovascular prevention
rimonabant
CRESCENDO, 2010      NCT	rimonabant	placebo			Low risk of bias	negative
RIO europe 20mg, 2005	rimonabant 20mg	placebo			Low risk of bias	suggesting
Rio-lipid 20 mg, 2005	rimonabant 20mg	placebo			Low risk of bias	suggesting
RIO-North America 20 mg, 2006      NCT	rimonabant 20mg	placebo			Low risk of bias	suggesting
RIO europe 5mg, 2005	rimonabant 5mg	placebo			Low risk of bias	-
RIO europe (20 vs 5 mg), 2005	rimonabant 20mg	rimonabant 5mg				-